Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$3.17 - $6.17 $12.7 Million - $24.7 Million
-4,000,000 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$4.16 - $13.72 $1.04 Million - $3.43 Million
250,000 Added 6.67%
4,000,000 $21.6 Million
Q3 2021

Nov 15, 2021

BUY
$13.07 - $18.84 $3.27 Million - $4.71 Million
250,000 Added 7.14%
3,750,000 $67.4 Million
Q2 2021

Aug 16, 2021

BUY
$16.52 - $20.4 $24.8 Million - $30.6 Million
1,500,000 Added 75.0%
3,500,000 $60.1 Million
Q1 2021

May 17, 2021

SELL
$16.56 - $25.46 $8.28 Million - $12.7 Million
-500,000 Reduced 20.0%
2,000,000 $40 Million
Q3 2020

Nov 16, 2020

SELL
$16.59 - $24.79 $8.3 Million - $12.4 Million
-500,000 Reduced 16.67%
2,500,000 $41.5 Million
Q1 2020

May 15, 2020

SELL
$14.47 - $27.96 $10.9 Million - $21 Million
-750,000 Reduced 20.0%
3,000,000 $53.6 Million
Q4 2019

Feb 14, 2020

BUY
$15.87 - $23.12 $11.9 Million - $17.3 Million
750,000 Added 25.0%
3,750,000 $80.9 Million
Q3 2019

Nov 14, 2019

BUY
$16.91 - $36.27 $8.46 Million - $18.1 Million
500,000 Added 20.0%
3,000,000 $54.6 Million
Q2 2019

Aug 14, 2019

BUY
$31.0 - $36.3 $15.5 Million - $18.2 Million
500,000 Added 25.0%
2,500,000 $89 Million
Q4 2018

Feb 14, 2019

BUY
$30.43 - $56.65 $15.2 Million - $28.3 Million
500,000 Added 33.33%
2,000,000 $65.7 Million
Q3 2018

Nov 14, 2018

SELL
$46.46 - $68.49 $23.2 Million - $34.2 Million
-500,000 Reduced 25.0%
1,500,000 $91.4 Million
Q2 2018

Aug 14, 2018

BUY
$46.25 - $104.45 $23.1 Million - $52.2 Million
500,000 Added 33.33%
2,000,000 $97.7 Million
Q1 2018

May 15, 2018

SELL
$57.4 - $108.44 $106 Million - $201 Million
-1,850,000 Reduced 55.22%
1,500,000 $159 Million
Q4 2017

Feb 14, 2018

SELL
$23.02 - $60.5 $42.6 Million - $112 Million
-1,850,000 Reduced 35.58%
3,350,000 $200 Million
Q3 2017

Nov 14, 2017

BUY
$17.79 - $24.0 $92.5 Million - $125 Million
5,200,000
5,200,000 $125 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Camber Capital Management LP Portfolio

Follow Camber Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Camber Capital Management LP with notifications on news.